Luke Ouma
Sarah Al-Ashmori
Samuel Sarkodie
Lou Whitehead
Ann Konkoth
et al. | Master protocols in low- and middle-income countries: a review of current use, limitations and opportunities for precision medicine | 2025 |
|
Luke Ouma
Sarah Al-Ashmori
Samuel Sarkodie
Shaun Hiu
Dorcas Kareithi
et al. | Master protocols in Low-and-Middle income countries: A review of current use, limitations, and opportunities for precision medicine | 2024 |
|
Dr Leher Gumber
Dr Opeyemi Agbeleye
Alex Inskip
Ross Fairbairn
Madeleine Still
et al. | Operational complexities in international clinical trials: a systematic review of challenges and proposed solutions | 2024 |
|
Dr Jingky Lozano-Kuehne
| A subset of non-small cell lung cancer patients treated with Pemetrexed show 18F-Fluorothymidine “Flare” on Positron Emission Tomography | 2023 |
|
Dr Jingky Lozano-Kuehne
Dr Nicola Cresti
| Author Correction: Results of the phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer (Nature Communications, (2022), 13, 1, (3246), 10.1038/s41467-022-30666-0) | 2023 |
|
Dr Jingky Lozano-Kuehne
| Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naïve patients with cancer: Updated safety data | 2023 |
|
Dr Jingky Lozano-Kuehne
| Spatial and temporal intra-tumoural heterogeneity in advanced High-Grade Serous Ovarian Cancer: implications for surgical and clinical outcomes | 2023 |
|
Dr Jingky Lozano-Kuehne
| [18F]Fluorothymidine(FLT)-PET imaging of thymidine kinase 1 pharmacodynamics in non-small cell lung cancer treated with pemetrexed | 2022 |
|
Dr Jingky Lozano-Kuehne
Dr Nicola Cresti
Professor Ruth Plummer
| Results of the Phase IIa RADICAL trial of the FGFR inhibitor AZD4547 in endocrine resistant breast cancer | 2022 |
|
Dr Jingky Lozano-Kuehne
| The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [18F]GE-226, a first-in-patient study | 2022 |
|
Dr Jingky Lozano-Kuehne
| Predictors for single-agent resistance in FIGO score 5 or 6 gestational trophoblastic neoplasia: an international, multicentre, retrospective study | 2021 |
|
Dr Jingky Lozano-Kuehne
| [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer | 2020 |
|
Dr Jingky Lozano-Kuehne
| Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy | 2020 |
|
Dr Jingky Lozano-Kuehne
| [18F] Fluciclatide PET as a biomarker of clinical response to combination therapy of pazopanib and paclitaxel in patients with platinum-resistant or platinum-refractory advanced ovarian cancer: Results of a phase Ib study | 2019 |
|
Dr Jingky Lozano-Kuehne
| [18F]Fluciclatide PET As A Biomarker Of Response To Combination Therapy Of Pazopanib And Paclitaxel In Platinum-resistant/refractory Ovarian Cancer | 2019 |
|
